Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03095456 · ClinicalTrials.gov registry record · Phase 3
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
A Phase 3 study, sponsored by Mylan.
- Completed
- Registry status
- Phase 3
- Development phase
- 207
- Enrollment target
NCT03095456: Completed Phase 3 study, sponsored by Mylan.
NCT03095456 is a Phase 3 study that has completed, run by Mylan. The registered enrollment target is 207 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03095456, a Phase 3 study, has completed, sponsored by Mylan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 207 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak Inspiratory Flow Rate.
Primary Outcome
FEV1 = forced expiratory volume at one second
Interventions
- DRUG Revefenacin
- COMBINATION_PRODUCT Spiriva Handihaler®
- DRUG Placebo for Revefenacin
- DRUG Placebo for Spiriva Handihaler®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2017-03-27 |
| Est. Completion | 2017-11-25 |
| Phase | Phase 3 |
What the finished NCT03095456 record still lists
NCT03095456 is an interventional study that assigns participants to a tested intervention. The registered 207 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 4 interventions - of which Revefenacin is the first listed.
NCT03095456 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03095456 about?
NCT03095456 is a clinical study titled "Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD". This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak Inspiratory Flow Rate.
What is the current status of trial NCT03095456?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 207 participants. The study started on 2017-03-27. Estimated completion is 2017-11-25.
What interventions are being tested in trial NCT03095456?
The interventions under investigation include: Revefenacin (DRUG), Spiriva Handihaler® (COMBINATION_PRODUCT), Placebo for Revefenacin (DRUG), Placebo for Spiriva Handihaler® (DRUG).
Who is sponsoring clinical trial NCT03095456?
This trial is sponsored by Mylan, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03095456's enrollment target sits among peer trials
207 1346th of 2000 higher than 654 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04353778 · 207 participants · Phase 1
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
- NCT05875805 · 207 participants · NA
A Telehealth Advance Care Planning Intervention
- NCT06254950 · 207 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
- NCT06904274 · 207 participants · Phase 3
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI